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Abstract: The complexity of the diagnosis and treatment of cancer means that it is often associated
with anxiety symptoms. The aim of our study was to further our understanding of the oncological
process and the presence of anxiety symptoms, from a gender perspective. A cross-sectional study
was performed, examining 402 medical records obtained by simple random sampling of oncology
patients at a hospital in northern Spain from July 2012 to July 2014. Data collection took place between
February and May 2015. Psychiatric and sociodemographic variables were gathered, as well as pain
variables and information regarding the oncological process. The data analysis included a descriptive
univariate analysis and a bivariate analysis, and a logistic regression model was performed. Our
results suggest that women with cancer suffer more anxiety symptoms than men with cancer. Women
with anxiety symptoms represented 76.5% of all patients with anxiety. The OR of suffering anxiety
symptoms between women and men was 2.43 (95% CI 1.05–5.63) (p = 0.04). A greater incidence of
anxiety symptoms was found in patients with cancer pain and oncological treatment with biological
therapy. Our results suggest that the gender perspective is necessary in the management of mental
health in patients with cancer. Nonetheless, further studies are necessary to confirm our findings.
Keywords: cancer; gender; anxiety; pain; side effects
1. Introduction
In 1946, the World Health Organization (WHO) defined overall health as “a complete state of
physical mental and social well-being and not only the absence of illness or disease” [1]. With regards
to this definition, we can conclude that mental health is an inherent part of physical health and that it
is practically impossible to feel healthy if we are lacking psychological wellbeing, although this is also
intimately related with our circumstances and our ability to adapt to these.
Although a large proportion of the global population suffers from mental disorders, it is difficult to
calculate their impact at an epidemiological level, as mental disorders are frequently underdiagnosed.
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The Mental Health Action Plan 2013–2020 published by the WHO [2] gathers the most relevant
epidemiological data regarding mental disorders. The WHO estimates that one out of every four
people, i.e., 25% of the worldwide population, will suffer a mental disorder during their lifetime.
Currently, 450 million people suffer from a mental illness.
The epidemiological magnitude of cancer also represents one of the largest public health burdens.
The Globocan 2018 database reported 18.1 million new cases in the year 2012, estimating that, in
2040, this will increase to 29.5 million new cancer diagnoses worldwide [3]. The complexity of the
oncological process, the diagnosis, treatment, secondary effects, and pain, among other aspects, are all
associated with greater emotional distress [4].
The magnitude of these pathological issues leads us to question how cancer and mental disorders
interact when they coexist, and indeed, many scientific publications have studied this relationship [5–7].
Thirty percent of oncological patients are estimated to suffer emotional distress during treatment [5–8].
Linden et al, reported that, on average, 19% of people with cancer present anxiety symptoms, and this
figure is twice as frequent in women.
Considering the most prevalent types of cancer, a level of clinical anxiety was reported in 7.5% of
men with prostate cancer, increasing to almost 28.4% of women with gynecological cancer [5]. However,
according to Watts et al, levels of anxiety in men with prostate cancer can reach up to 27.04% prior to
receiving treatment, decreasing to 15% during treatment and to 18.5% after completing treatment [6].
In contrast, Maas et al, studied anxiety in women with breast cancer, reporting a prevalence ranging
between 17.9% and 33.3% [7].
In this context, our aim was to further our understanding of anxiety symptoms and the oncological
process from a gender perspective, among a sample of oncological patients from a hospital in
northern Spain.
2. Materials and Methods
The study protocol was approved by the Cantabria Clinical Research Ethics Committee on 29 May
2014; this was prior to data acquisition, which began in February 2015. The relevant authorization was
also obtained in line with hospital regulations. The data were treated anonymously and confidentially
under Spanish Organic Law 15/1999 of 13 December on Personal Data Protection [9]. Because the data
were analyzed anonymously, obtaining patient consent to research their data was deemed unnecessary.
2.1. Study Design and Participants
A cross-sectional study was performed. The eligibility criteria were patients aged over 18 years
with any type of cancer (oncological and/or hematological malignances), of both sexes, and treated at
the Oncology Unit of Hospital University Marqués of Valdecilla (National Public Health System of
Spain) in northern Spain between 1 July 2012 and 1 July 2014. In total, 420 Oncology Unit patients
were selected by simple random sampling from 2661 in total (Figure 1). We obtained the information
of the medical records (medical records and nursing assessments). We considered the medical records
incomplete when information about all anxiety related variables was missing. We considered the
records complete if they contained information about >80% of the remaining variables. If the medical
records were incomplete, we withdrew that patient from the study. As a result, of the 420 original
subjects, records from 18 patients (4.3%) were removed.
The following criteria were used to determine the sample size. Regarding prevalence rates,
the literature available is scarce, therefore, the sample size was calculated by assuming maximum
indeterminacy (p = 0.5). Under this assumption, with a 95% confidence interval for a maximum error
of 5%, a sample of 400 patients was estimated.
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Figure 1. Overall study flow. 
The following criteria were used to determine the sample size. Regarding prevalence rates, 
the literature available is scarce, therefore, the sample size was calculated by assuming maximum 
indeterminacy (p = 0.5). Under this assumption, with a 95% confidence interval for a maximum 
error of 5%, a sample of 400 patients was estimated.  
2.2. Data Sources and Variables 
We collected data between February and May 2015. Based on patient medical records and 
nursing assessments, we obtained information for each cancer patient who underwent active 
treatment from 1 July 2012 to 1 July 2014. Full oncological and psychiatric details were accessed. 
The following variables were gathered: 
 Anxiety symptoms: patients diagnosed with anxiety symptoms by a clinician specialized in 
psychiatry, following the criteria of the American Psychiatric Association as stated in the 
DSM-V [10].  
 Sociodemographic variables: age, sex, marital status, number of children, and education level. 
 Psychiatric symptoms: psychiatric diagnosis, psychiatric treatment, anxiety crises, and use 
of relaxation techniques.  
Figure 1. verall study flo .
2.2. Data Sources and Variables
We collected data b tween February and May 2015. Based on patien medical records and nursing
assessments, we obtained information for each cancer p tient who underwent active treatment from
1 July 2012 to 1 July 2014. Full oncological and psychiatric details were accessed. The following
variables were gathered:
• Anxiety symptoms: patients diagnosed with anxiety symptoms by a clinician specialized
in psychiatry, following the criteria of the American Psychiatric Association as stated in the
DSM-V [10].
• Sociodemographic variables: age, sex, marital status, number of children, and education level.
• Psychiatric symptoms: psychiatric diagnosis, psychiatric treatment, anxiety crises, and use of
relaxation technique .
• Pain aracteristics: pres n e of pain, location of pain, intensity of pain, nd pain control.
The presence of pain was treated dichotomously (yes/no). In patients whose pain was treated
with analgesics, the type of nalg sic, route of administ ation, and intensity of pain were
recorded. The latter was measured following the recommendatio s of the European Soci ty
for M dic l Oncology sing the Visual Analogue Scale [11], from 0 (‘no pain’) to 10 (‘extreme
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pain’). Self-perceived pain control, reported by the patients themselves, was recorded in the
nursing history; this information was obtained directly from the medical record. The ‘pain control’
variable was categorized into ordinal levels: ‘no pain’, ‘adequate pain control’, and ‘inadequate
pain control’. The Oncology Unit followed the most recent recommendations of the European
Society for Medical Oncology to determine the prescription of analgesic treatment [11].
• Oncological process characteristics: type of cancer (location), cancer treatment (chemotherapy,
radiotherapy, hormone therapy, biological therapy, and/or surgery), and any side effects of cancer
treatment. The symptoms considered as being side effects were those established by the National
Cancer Institute [12].
2.3. Data Analysis
The data analysis included a descriptive univariate analysis and a bivariate analysis of the
characteristics by the indicator of Anxiety Symptoms. The bivariate analysis was done globally
and also stratified by gender. Mean, Standard Deviation (SD), and Mean Confidence Interval were
presented for continuous variables, and the contrast between Anxiety Symptoms of the patients was
done with the Wilcoxon two-sample test (W). In case of categorical variables, we presented counts and
percentage of the sample, using the Pearson’s Chi-Square test, Likelihood ratio (LR) chi-square test or
Fisher’s exact test to contrast differences between groups.
A logistic regression model was performed to analyze the explanatory variables that influence the
variable: Anxiety Symptoms. The selection of variables was carried out by “backward” automatic
procedure. We established a logistic regression to assess differences in the probability of suffering
Anxiety Symptoms according to the different explanatory variables. The estimated Odds Ratios (OR)
between each pair of categories were presented (p values were corrected taking into account the Tukey
adjustment for multiple comparison).
All statistical analyses were performed using SAS v9.4 (SAS Institute Inc., Cary, NC, USA)
Statistical decisions have been made taking the value 0.05 as a level of significance
3. Results
3.1. Sociodemographic Characteristics of the Total Sample and According to Anxiety Symptoms and Gender
In total, 402 medical histories were reviewed, of which, 57.5% were women with a mean age
of 61.2 [SD 13.1] (See Table 1). The mean age of patients without anxiety symptoms was 61.6 years
[SD 12.9] compared to 59.6 years [SD 13.8] in the case of patients with anxiety. Women represented
76.5% (n = 62) of patients with anxiety this finding was statistically significant (p < 0.01).
In the case of female patients, in both groups (with and without anxiety symptoms), over 70% of
women were married (n = 119; n = 42), between 10% to 15% (n = 22; n = 6) of women were single, and
between 5% to 10% were widows (n = 7; n = 6). In both groups, 75% had children. The median was
two children. Approximately 65% of female patients (n = 105; n = 38) had a basic education, between
15% to 20% (n = 26; n = 20) had vocational training, and 15% (n = 23; n = 8) had university degrees.
In the case of men, in both groups there were over 70% of married men (n = 103; n = 12), and
between 15% to 18% (n = 19; n = 3) of single men. Between 65% to 70% (n = 92; n = 11) of men had
children, with a median of two children. Almost half of the male patients (n = 52; n = 7) had basic
studies, between 20% to 30% (n = 39; n = 3) had vocational training and almost 30% (n = 34; n = 4) had
university studies.
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Table 1. Sociodemographic characteristics of the total sample and according to the presence of anxiety symptoms.
Characteristics
Total (n = 402) Anxiety Symptoms
Anxiety Symptoms
Female Male
n (%) No (n = 321) Yes (n = 81) No (n = 169) Yes (n = 62) No (n = 152) Yes (n = 19)
AGE (years), Mean
[SD]
61.2; [SD 13.1]
(95% CI 59.9–62.5)
61.6; [SD 12.96]
(95% CI 60.2–62.9)
59.6;
[SD = 13.8] (95%
CI 56.5–62.7)
60.7; [SD 12.4]
(95% CI 57.4–63.9)
58.5;
[SD 13.6] (95% CI
54.9–62.1)
62.6;
[SD 13.5] (95% CI
59.2–65.9)
63.1;
[SD 14.4] (95% CI
59.6–66.6)
p = 0.29 a p = 0.32a p = 0.67 a
Gender
Male 171 (42.5%) 152 (47.4%) 19 (23.5%)
Female 231 (57.5%) 169 (52.7%) 62 (76.5%)
p < 0.01 b
Marital Status
Married 276 (68.6%) 119 (78.8%) 42 (72.4%) 103 (79.8%) 12 (70.6%)
Single 50 (12.4%) 22 (14.6%) 6 (10.3%) 19 (14.7%) 3 (17.7%)
Divorced 9 (2.2%) 3 (1.9%) 3 (5.2%) 2 (1.6%) 1 (5.9%)
Widowed 18 (4.5%) 7 (4.6%) 6 (10.3%) 4 (3.1%) 1 (5.9%)
Separated 2 (0.5%) 1 (1.7%) 1 (0.8%)
p = 0.15c p = 0.78c
Children 267 (66.4%) 117 (77.5%) 47 (81%) 92 (71.3%) 11 (64.7%)
p = 0.57c p = 0.58c
Number of Children
Mean [SD]
1.8; [SD1.0]
(IC95%1.7–1.9)
1.8;
[SD 1.0]
(95% CI 1.6–1.9)
2;
[SD 1.3]
(95% CI 1.6–2.4)
1.8;
[SD 0.9]
(95% CI 1.6–1.9)
2.1;
[SD 1.1]
(95% CI 1.3–2.9)
p = 0.43 a p = 0.39 a
Educational Level
Elementary 202 (50.2%) 105 (68.2%) 38 (65.5%) 52 (41.6%) 7 (50%)
Secondary 80 (19.9%) 26 (16.9%) 12 (20.7%) 39 (31.2%) 3 (21.4%)
University 69 (17.2%) 23 (14.9%) 8 (13.8%) 34 (27.2%) 4 (28.6%)
p = 0.81 b p = 0.72 c
a Wilcoxon Two-Sample Test. b Chi-Squared Test. c LR-Chi-Squared Test. SD: Standard Deviation. CI: Confidence Interval.
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3.2. Psychiatric, Cancer Pain, and Oncological Treatment Characteristics of Patients According to Anxiety
Symptoms and Gender
3.2.1. Psychiatric Characteristics of Patients according to Anxiety Symptoms and Gender
Up to 6.5% (n = 26) of patients had a psychiatric diagnosis, of which, 73.1% (n = 19) also presented
anxiety symptoms (See Table 2).
Up to 27.4% (n = 17) of women with anxiety symptoms had a mainly anxious and/or depressive
psychiatric diagnosis, and this diagnosis came after the beginning of the peri-oncological process
(n = 13; 76.5%). Nonetheless, the percentage of patients who suffered anxiety crises was low (n = 3;
4.8%). Only 12.90% (n = 8) had psychological treatment with a weekly or monthly frequency. Up to
8.06% (n = 5) performed some type of relaxation technique.
In the case of men, only 10.5% (n = 2) had a psychiatric diagnosis, in all cases this was a depressive
type, and the diagnosis was made prior to the peri oncological process. One suffered anxiety crises
(n = 1; 5.3%). Only one patient received psychological treatment (n = 1; 5.3%) on a monthly basis. Only
one patient performed some type of relaxation technique.
Women presented a greater prevalence of psychiatric diagnoses compared to men (p < 0.01).
3.2.2. Pain Characteristics of Patients according to Anxiety Symptoms and Gender
Anxiety symptoms and pain were present in 29% (n = 18) of women and 63.2% (n = 12) of men.
This difference was statistically significant compared to patients without pain (p < 0.01; p = < 0.01) (See
Table 2).
The intensity of pain was similar in men and women with and without anxiety symptoms. La
Table S1 shows the consumption of analgesics included NSAIDs, other non-opioid analgesics and both
weak and strong opioids. Oral administration of analgesics was most frequent. Regarding the need
for rescue analgesia, this was required by 61.1% (n = 11) of women and 63.6% (n = 7) of men with
anxiety symptoms.
The effectiveness of the analgesic varied between “total control (45.8%; n = 33) and “partial
control” (54.2%; n = 39) of symptoms, almost in equal proportion in both groups (with and without
anxiety symptoms). No patients referred a total lack of control of symptoms.
No statistically significant differences were found in the remaining variables except for the need
for rescue analgesia in the case of women (p = 0.01).
The location of pain varied, for which 11 different locations were described (See Table S2).
3.2.3. Characteristics of the Oncological Treatment according to Anxiety Symptoms and Gender
In both groups, women were primarily treated with chemotherapy (91.7% n = 155; 95.2% n = 59)
and intravenous administration of it was most frequent (91.6% n = 142; 98.3% n = 58) (See Table 2).
No statistically significant variables were detected in any variable related to the oncological
process, except for treatment with radiation therapy in women, where the prevalence of anxious
symptoms was significantly greater (p < 0.01).
Men were primarily treated with chemotherapy in both groups (90.1% n = 137; 73.7% n = 14) for
which intravenous administration of therapy was most frequent (93.4% n = 128; 85.7% n = 12).
Statistically significant differences were found (p = 0.04) regarding treatment with chemotherapy
in men, where the number of patients without anxiety symptoms and chemotherapy treatment
was greater.
The distribution of the oncological diagnoses according to the anxiety symptoms and gender are
described in Table S3.
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Table 2. Psychiatric, cancer pain, and oncological treatment characteristics of patients according to anxiety symptoms and gender.
Psychiatric, cancer pain and oncological treatment characteristics Total (n = 402)
n (%)
Anxiety Symptoms
Female Male
No (n = 169) Yes (n = 62) No (n = 152) Yes (n = 19)
Psychiatric diagnosis 26 (6.5%) 5 (2.9%) 17 (27.4%) 2 (1.3%) 2 (10.5%)
p ≤ 0.01 a p = 0.06 b
Type of psychiatric diagnosis
Paranoid schizophrenia 3 (11.5%) 1 (20%) 1 (6.3%) 1 (50%) –
Adjustment disorder with anxiety 2 (7.7%) – 2 (12.5%) – –
Adjustment disorder with mixed anxiety and depressed mood 5 (19.2%) 1 (20%) 3 (18.8%) 1 (50%) –
Adjustment disorder with depressed mood 14 (53.8%) 2 (40%) 10 (62.5%) – 2 (100%)
Unspecified psychotic disorder 1 (3.8%) 1 (20%) – – –
Previous psychiatric Diagnosisc 7 (26.9%) 2 (40%) 4 (23.5%) 1 (50%) –
p = 0.59 b
Anxiety crisis 4 (0.9%) – 3 (4.8%) – 1 (5.3%)
Type of treatment-psychiatric/psychological
Psychiatric – – – – –
Psychological 9 (100%) – 8 (100%) – 1 (100%)
Frequency Psychiatric/psychological treatment
Weekly 3 (33.3%) – 3 (37.5%) – –
Monthly 6 (66.7%) – 5 (62.5%) – 1 (100%)
Relaxation techniques 6 (1.5%) – 5 (8.1%) – 1 (5.3%)
cancer pain 74 (18.4%) 16 (9.5%) 18 (29%) 28 (18.4%) 12 (63.2%)
p < 0.01 a p < 0.01 a
IntensityMean [SD]d
5.6; [SD1.4]
(95% CI 5.3-6)
5.44; [SD1.3]
(95% CI
5.2-5.6)
5.61; [SD1.3]
(95% CI 5.3-6)
5.61; [SD1.6]
(95% CI 5.4-6)
5.92; [SD1.3]
(95% CI
5.29-6.6)
p = 0.71 e p = 0.58 e
Analgesic USE 72 (97.3%) 16 (100%) 18 (100%) 27 (96.4%) 11 (91.7%)
p = 0.52 f p = 0.52 b
Oncological treatment
chemotherapy 365 (90.8%) 155 (91.7%) 59 (95.2%) 137 (90.1%) 14 (73.7%)
p = 0.37 a p = 0.04 a
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Table 2. Cont.
Psychiatric, cancer pain and oncological treatment characteristics Total (n = 402)
n (%)
Anxiety Symptoms
Female Male
No (n = 169) Yes (n = 62) No (n = 152) Yes (n = 19)
Route of administration
Endovenous 340 (93.2%) 142 (91.6%) 58 (98.3%) 128 (93.4%) 12 (85.7%)
p = 0.08 a p = 0.29 a
Oral 75 (20.5%) 27 (17.4%) 10 (16.9%) 35 (25.6%) 3 (21%)
p = 0.94 a p = 0.74 a
Subcutaneous 3 (0.8%) 1 (0.7%) – 2 (1.5%) –
Radiation therapy 178 (48.8%) 73 (43.2%) 39 (62.9%) 57 (37.5%) 9 (47.4%)
p < 0.01 a p = 0.4 a
Hormonal therapy 56 (13.9%) 38 (22.5%) 16 (25.8%) 2 (1.3%) –
p = 0.6 a
Biological therapy 124 (30.8%) 54 (31.9%) 23 (37.1%) 37 (24.3%) 10 (52.6%)
p = 0.46 a p = 0.01 a
Surgery 190 (74.3%) 91 (53.9%) 35 (56.5%) 57 (37.5%) 7 (36.8%)
p = 0.72 a p = 0.95 a
a Chi-Squared Test. b Fisher’s Exact Test. c Psychiatric diagnosis prior to the oncological peri-diagnosis. d Visual Analogue Scale. e Wilcoxon Two-Sample Test. f LR-Chi-Squared Test. SD:
Standard Deviation.
Int. J. Environ. Res. Public Health 2020, 17, 1302 9 of 12
In total, 34 different diagnoses were detected. In women, the most frequent diagnosis was breast
cancer with 69 (40.8%) patients without anxiety symptoms compared to 42 (67.7%) patients with
anxiety symptoms. In men, the most common diagnosis was rectal cancer with 37 (24.3%) patients
without anxiety symptoms and 3 (15.8%) patients with anxiety symptoms.
The secondary effects (Table S4) of the oncological treatments are multiple and diverse. Thirty-five
different symptoms were detected. In women, statistically significant differences were observed
regarding anxiety symptoms in patients who referred: alopecia (p < 0.01), asthenia (p < 0.01),
arthralgias (p < 0.01), mucositis (p = 0.02), weight loss (p = 0.02), nail toxicity (p = 0.04) and insomnia
(p < 0.01).
3.3. Logistic Regression Model
The explanatory variables that were included in the logistic regression were: Gender, Cancer Pain,
Biological Therapy, and Location of Cancer. Table S5 shows the Type III Effects.
Table S6 shows the distribution of anxiety symptoms according with the explanatory variables.
Table 3 shows the odds ratio of the explanatory variables.
Table 3. Odds ratio.
Effect Category 1 Category 2
Contrast
t Value DF Ajusted p Value OR 95% CI
Gender Female Male 2.08 394 0.04 2.43 1.05 5.63
Cancer pain Yes No 5.37 394 <0.0001 6.06 3.13 11.73
Biological therapy Yes No 2.21 394 0.03 1.89 1.07 3.32
Location of cancer Ginecological
Gastrointestinal 2.62 394 0.07 3.18 1.34 7.56
Respiratory 1.97 394 0.28 3.59 1.00 12.84
Hematological 2.60 394 0.07 3.63 1.37 9.60
Up to 26.8% of women and 11.1% of men suffered anxiety symptoms. The OR of suffering anxiety
symptoms between women and men was 2.43 (95% CI 1.05–5.63). This difference was statistically
significant (p = 0.04).
Up to 15.6% without cancer pain and 40.5% with cancer pain suffered anxiety symptoms. The OR
of suffering anxiety symptoms according cancer pain was 6.06 (95% CI 3.13–11.73). This difference was
statistically significant (p < 0.0001).
Up to 17.3% without biological therapy and 26.6% with biological therapy suffered anxiety
symptoms. The OR of suffering anxiety symptoms according oncological treatment with biological
therapy was 1.89 (95% CI 1.07–3.32). This difference was statistically significant (p = 0.03).
Although there was a statistically significant influence in considering the variable Location of
cancer (F = 3.32; p = 0.01, see Table S5), there were no statistically significant differences across each
pair of locations of cancer.
4. Discussion
Our results suggest that women with cancer suffer more anxiety symptoms than men with cancer.
These findings coincide with other authors, such as Linden et al. [5], who also identified greater anxiety
in women with cancer, compared to men.
The greater incidence of anxiety in women is not exclusive of oncology. As noted by Donner
and Lowry [13], the US National Institute of Mental Health estimates that women have 60% more
probabilities of developing an anxiety disorder throughout their life. Indeed, in our study, 27.4% of
women with anxiety symptoms presented a prior psychiatric diagnosis and, in most cases, this was of
a depressive/anxious type. In contrast, only 10.5% of men presented a previous psychiatric diagnosis.
It is estimated that 30% of people with cancer suffer some type of emotional distress [5–8]; if we
add the coexistence of pain, the probabilities of suffering anxiety symptoms increase. Almost 20%
of our patients suffered pain, which increased up to 30% and 60% in women and men with anxiety
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symptoms, respectively. Stanton et al. [14], revealed that pain is present in 20% to 50% of patients with
cancer. Furthermore, according to Mehnert et al. [15], it can reach up to 90% in the final stages of the
disease. In our patients, the presence of pain was significantly greater, both in men and women, in
the group with anxiety symptoms. Besides, the OR of suffering anxiety symptoms according cancer
pain was higher. This data is logical if we consider the loss of quality of life when suffering pain
that is more or less intense over a prolonged period of time. Several publications relate pain with
anxiety as this involves an important loss of quality of life of patients with cancer [16–18]. On occasion,
pharmacological treatments for pain and anxiety can be the same. However, despite the fact that the
WHO, the American Cancer Society, and the European Society for Medical Oncology [11,19,20] include
the use of psychotropic drugs in their guidelines on the management of oncological pain, consumption
of these is not always related with greater pain control in patients with cancer [4].
The control of anxiety in cancer patients is particularly difficult considering the complexity of
the cancer process, the level of uncertainty, and the fear of death, all of which can generate feelings of
anguish in patients. Some of our patients practiced relaxation techniques to control anxiety symptoms.
Indeed, following this perspective, Parás-Bravo et al, reported quality of life improvements via an
intervention for the reduction of anxiety in cancer patients [16].
Lastly, the presence of side effects, mainly due to radiation therapy and chemotherapy, were
closely related with anxiety symptoms in women. Some secondary effects also negatively influence
body image and the performance of activities of daily living and leisure which can, in turn, increase
anxiety symptoms and affect quality of life [21,22]. The OR of suffering anxiety symptoms according
oncological treatment with biological therapy was higher. This could be due to the side effects of
these therapy.
Powell et al. [23] emphasize the importance of the psychological adaptation to the secondary
effects of therapies against cancer, and Kayl and Meyers [24] underline the need to design intervention
guidelines to control the adverse effects and reduce the negative impact that these have on the quality
of life of patients.
Limitations
In retrospective studies based on secondary information (registers), the quality of information may
be poor due to incomplete records or a lack of agreement between the different records available. For this
reason, we purposely selected the homogeneous variables that could be gathered from secondary
records. The study protocol included the individual verification of discrepancies (contradictory
information) with the doctors and nurses responsible for the patient; we conducted a sensitivity
analysis by incorporating the information separately. A 100% agreement was found for the variables
under study.
One of the possible limitations of this study is the lack of statistical power. This means that certain
associations may not reach statistical significance. Thus, in the groups with the diagnosis of anxiety
symptoms, the sample size of the groups is too small. The analysis included patients with a previous
psychiatric diagnosis; however, due to their small number, it was considered statistically irrelevant.
A further limitation is that the location of the cancer was not homogeneous in our sample. Finally,
it should be noted that anxiety may appear as a consequence of cancer treatment.
5. Conclusions
The results of our study suggest that gender differences exist regarding the suffering of anxiety
symptoms in oncological patients. The women in our sample presented greater anxiety than men.
Many factors can influence these symptoms. In the present sample, the most important factors were
the presence of pain and oncological treatment with biological therapy. In many fields, the gender
perspective is present; however, in health issues, gender is highly relevant due to its repercussions.
The WHO recognizes gender as being a determinant of health and with the Strategy on Women’s
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Health and Well-being in the WHO European Region, the gender perspective is presented as a means
to achieve gender equity [25]. Nonetheless, further research is necessary to confirm our findings.
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